Last reviewed 2026-04-23 · How we verify

CS1001+ Fluorouracil+Cisplatin

CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects.

CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects. Used for Gastric or gastroesophageal junction cancer, Esophageal squamous cell carcinoma.

At a glance

Mechanism of action

CS1001 (an anti-PD-L1 monoclonal antibody) restores T-cell-mediated anti-tumor immunity by blocking the PD-L1/PD-1 interaction. When combined with fluorouracil (a pyrimidine antimetabolite) and cisplatin (a platinum-based alkylating agent), the chemotherapy agents provide direct cytotoxic effects while potentially enhancing immunogenicity, creating a synergistic triple-modality approach for solid tumors.

Approved indications

• Gastric or gastroesophageal junction cancer
• Esophageal squamous cell carcinoma

Common side effects

• Nausea and vomiting
• Myelosuppression (anemia, neutropenia, thrombocytopenia)
• Fatigue
• Immune-related adverse events (pneumonitis, hepatitis, colitis)
• Nephrotoxicity
• Peripheral neuropathy

Key clinical trials

• A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CS1001+ Fluorouracil+Cisplatin CI brief — competitive landscape report
• CS1001+ Fluorouracil+Cisplatin updates RSS · CI watch RSS
• CStone Pharmaceuticals portfolio CI